
Annual report 2025
added 04-15-2026
NanoVibronix Long-Term Debt 2011-2026 | NAOV
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt NanoVibronix
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 28 K | 64 K | - | - | - | 18 | - | - | - | - | - | - | - | 1.95 M | 1.45 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.95 M | 18 | 698 K |
Quarterly Long-Term Debt NanoVibronix
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15 K | 69 K | 1.25 M | 64 K | 77 K | 89 K | 86 K | - | - | - | - | - | - | - | - | - | 10 K | 12 K | 14 K | 18 K | 18 K | 18 K | 18 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.25 M | 10 K | 126 K |
Long-Term Debt of other stocks in the Medical devices industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
71.3 M | - | - | $ 1.77 B | ||
|
AdaptHealth Corp.
AHCO
|
1.72 B | $ 12.92 | -1.22 % | $ 1.75 B | ||
|
Allied Healthcare Products
AHPI
|
2.93 K | - | 3.58 % | $ 2.21 M | ||
|
Apollo Endosurgery
APEN
|
34 M | - | - | $ 475 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
430 K | - | -5.86 % | $ 30.6 M | ||
|
Avinger
AVGR
|
1.1 M | - | -20.74 % | $ 369 K | ||
|
Electromed
ELMD
|
1.1 M | $ 25.3 | 0.8 % | $ 214 M | ||
|
Axonics Modulation Technologies
AXNX
|
7.56 M | - | - | $ 3.31 B | ||
|
EDAP TMS S.A.
EDAP
|
2.16 M | $ 3.32 | 0.3 % | $ 124 M | ||
|
Aziyo Biologics
AZYO
|
3.59 M | - | 1.37 % | $ 20.5 M | ||
|
BIOLASE
BIOL
|
11.8 M | - | -13.19 % | $ 166 K | ||
|
BioSig Technologies
BSGM
|
103 K | - | 37.08 % | $ 85.7 M | ||
|
Conformis
CFMS
|
20.6 M | - | - | $ 16.4 M | ||
|
ClearPoint Neuro
CLPT
|
49.1 M | $ 10.45 | 1.06 % | $ 296 M | ||
|
Cardiovascular Systems
CSII
|
1.33 M | - | 0.15 % | $ 844 M | ||
|
Cytosorbents Corporation
CTSO
|
16.7 M | $ 0.63 | -1.29 % | $ 39.2 M | ||
|
CryoLife, Inc.
CRY
|
290 M | - | -4.14 % | $ 702 M | ||
|
Helius Medical Technologies
HSDT
|
12 K | $ 2.01 | 1.52 % | $ 1.22 M | ||
|
IRIDEX Corporation
IRIX
|
98 K | $ 1.06 | 2.43 % | $ 18 M | ||
|
Itamar Medical Ltd.
ITMR
|
154 K | - | 0.03 % | $ 1.58 B | ||
|
Dynatronics Corporation
DYNT
|
1.11 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
11.9 M | - | - | $ 10.2 M | ||
|
Misonix, Inc.
MSON
|
38.6 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
7.64 M | - | - | $ 111 M | ||
|
OrthoPediatrics Corp.
KIDS
|
99.8 M | $ 14.68 | 0.27 % | $ 344 M | ||
|
Butterfly Network
BFLY
|
20.4 M | $ 4.46 | -9.45 % | $ 944 M | ||
|
Second Sight Medical Products
EYES
|
17.1 M | - | -0.97 % | $ 54.4 M | ||
|
Intersect ENT, Inc.
XENT
|
63.6 M | - | - | $ 955 M | ||
|
LivaNova PLC
LIVN
|
345 M | $ 58.91 | -0.02 % | $ 3.21 B | ||
|
GBS
GBS
|
1.65 M | - | -0.57 % | $ 7.12 M | ||
|
Globus Medical
GMED
|
436 K | $ 89.55 | 1.99 % | $ 12.1 B | ||
|
Delcath Systems
DCTH
|
835 K | $ 10.23 | 0.2 % | $ 366 M | ||
|
PAVmed
PAVM
|
1.68 M | $ 8.54 | -4.32 % | $ 5.73 M | ||
|
Insulet Corporation
PODD
|
931 M | $ 168.16 | 5.07 % | $ 11.8 B | ||
|
CONMED Corporation
CNMD
|
834 M | $ 37.38 | 3.95 % | $ 1.16 B | ||
|
Inspire Medical Systems
INSP
|
30 M | $ 53.3 | -0.21 % | $ 1.57 B | ||
|
Integer Holdings Corporation
ITGR
|
1.19 B | $ 87.37 | 4.42 % | $ 3.03 B | ||
|
Sintx Technologies
SINT
|
2.84 M | $ 2.07 | 4.02 % | $ 5.74 M | ||
|
Edwards Lifesciences Corporation
EW
|
598 M | $ 81.79 | 0.7 % | $ 47.8 B | ||
|
Invacare Corporation
IVC
|
354 M | - | - | $ 24.7 M | ||
|
Stryker Corporation
SYK
|
14.9 B | $ 316.83 | 0.54 % | $ 121 B | ||
|
Tactile Systems Technology
TCMD
|
16 M | $ 22.39 | -0.49 % | $ 512 M | ||
|
TELA Bio
TELA
|
55.7 M | $ 0.89 | 3.5 % | $ 41.8 M | ||
|
LENSAR
LNSR
|
1.99 M | $ 5.39 | - | $ 64.5 M | ||
|
TransMedics Group
TMDX
|
453 M | $ 98.3 | -0.27 % | $ 3.34 B | ||
|
Tandem Diabetes Care
TNDM
|
310 M | $ 18.53 | 2.04 % | $ 1.26 B |